The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir (Yeztugo®) ...

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

Gilead Sciences Inc. closed 5.60% below its 52-week high of $119.96, which the company achieved on March 10th.

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...